SOLIRIS (eculizumab) - Myasthenia

Opinions on drugs - Posted on May 17 2024

Reason for request

Indication extension

Summary of opinion

Unfavourable opinion for reimbursement in the treatment of refractory generalised myasthenia gravis (gMG) in patients aged 6 years and above who are antiacetylcholine receptor (AChR) antibody-positive.

Clinical Benefit

Insufficient

The Committee deems that the clinical benefit of SOLIRIS (eculizumab) is insufficient to justify public funding in the treatment of refractory generalised myasthenia gravis (gMG) in patients aged 6 years and above who are antiacetylcholine receptor (AChR) antibody-positive.